GeoVax Labs, Inc. (GOVX) News
Filter GOVX News Items
GOVX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
GOVX News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest GOVX News From Around the Web
Below are the latest news stories about GEOVAX LABS INC that investors may wish to consider to help them evaluate GOVX as an investment opportunity.
GeoVax to Review 2024 Progress at the Emerging Growth Conference on January 16, 2025Company to provide updates on progress toward the BARDA-funded Phase 2b trial of GEO-CM04S1, its next-generation COVID-19 vaccine as well as for Gedeptin(R) (solid tumor therapy) and GEO-MVA (Mpox/Smallpox vaccine) ATLANTA, GA - January 8, 2025 (NEWM... |
GeoVax to Review 2024 Progress at Biotech Showcase During J.P. Morgan Healthcare Week 2025ATLANTA, GA - January 6, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that David Dodd, Chief Executive Officer, will r... |
GeoVax Receives Notice of Allowance For Cancer Vaccine PatentAdds to Growing Portfolio of Intellectual Property Assets ATLANTA, Ga., Dec. 09, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for Patent Application No. 17/876,682 to GeoVax, titled “Vaccinia Viral Vectors Encoding Chimeric Virus Like Particles.” The allowed claims add to GeoVax’s intellec |
GeoVax to Present at the Noble Capital Markets Twentieth Annual Emerging Growth Equity ConferenceATLANTA, Nov. 26, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced that its Chairman & CEO, David Dodd, will present at NobleCon20 - the Noble Capital Markets Twentieth Annual Emerging Growth Equity Conference taking place December 2-5, 2024 in Boca Raton, FL. Presentation Details:Speaker: David Dodd, Chairman & CEO Date/Time: December 3, 2024, 11:30 am ET Location: Florida Atl |
GeoVax Announces Positive Interim Data Review for Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic LeukemiaGEO-CM04S1 Improved Immune Response vs mRNA Vaccine ATLANTA, Nov. 19, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the completion of an interim data review by the Data Safety Monitoring Board (DSMB) for the ongoing Phase 2 clinical trial of GEO-CM04S1, GeoVax’s dual-antigen next-generation COVID-19 vaccine, as a booster vaccine for patients with chronic lymphocyt |
Geovax Labs Inc (GOVX) Q3 2024 Earnings Call Highlights: Strategic Advances and Financial ChallengesGeovax Labs Inc (GOVX) secures a major BARDA award and reports increased revenues, while navigating financial hurdles and competitive pressures. |
GeoVax Reports Third Quarter 2024 Financial Results and Provides Business UpdateProgress in GEO-CM04S1 BARDA/Project NextGen Phase 2b trial; multiple data readouts of existing COVID-19 vaccine Phase 2 trials expected during fourth quarter 2024 Gedeptin® on track to advance into Phase 2 clinical trial for first recurrent head and neck cancer in the first half of 2025 GEO-MVA Mpox vaccine advancing with cGMP clinical batch anticipated during fourth quarter 2024 Company to host conference call and webcast today at 4:30 p.m. ET ATLANTA, Nov. 12, 2024 (GLOBE NEWSWIRE) -- GeoVax |
GeoVax Labs initiated with a Buy at Alliance Global PartnersAlliance Global Partners analyst James Molloy initiated coverage of GeoVax Labs (GOVX) with a Buy rating and $15 price target Lead candidate GEO-CM04S1 is a “potentially best-in-class” COVID-19 prophylactic with potential in both healthy and immunocompromised patients, notes the analyst, who attributes $12.25 per share in value to CMO4S1. The firm also attributes $2 per share in value to Gedeptin, a head and neck cancer injectable therapeutic that the company is also advancing, along with cash a |
GeoVax to Report Third Quarter 2024 Financial Results and Provide Corporate Update on November 12, 2024GeoVax to Host Conference Call at 4:30 PM ET ATLANTA, Nov. 05, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that it will report third quarter 2024 financial results on Tuesday, November 12, 2024, after the close of U.S. markets. Following the release, management will host a live conference call and webcast, including Q&A, at 4:30 p.m. ET to provide a corporate up |
Geovax Labs Inc (GOVX) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial ...Geovax Labs Inc (GOVX) navigates significant BARDA funding and clinical advancements while addressing cash flow and competitive pressures. |